Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18177839 | 0.85 | SMN1; SMN2 (0.74) | SMN1; SMN2RECQLALDH1A1KDM4EKMT2A | |
| SCHEMBL1029651 | 0.85 | RECQL (0.73) | SMN1; SMN2RECQLALDH1A1KDM4EKMT2A | |
| SCHEMBL21164685 | 0.85 | SMN1; SMN2 (0.73) | SMN1; SMN2RECQLALDH1A1KDM4EKMT2A | |
| SCHEMBL3709310 | 0.83 | RECQL (0.70) | SMN1; SMN2RECQLALDH1A1KDM4EACHE | |
| SCHEMBL24163317 | 0.82 | RECQL (0.69) | SMN1; SMN2RECQLALDH1A1KDM4EKMT2A | |
| Hydrochloric Acid SCHEMBL3706762 | 0.82 | RECQL (0.68) | SMN1; SMN2RECQLALDH1A1KDM4EACHE | |
| SCHEMBL3956954 | 0.81 | MC4R (0.69) | SMN1; SMN2RECQLALDH1A1KDM4EACHE | |
| SCHEMBL3961457 | 0.80 | SMN1; SMN2 (0.66) | SMN1; SMN2RECQLALDH1A1KDM4EKMT2A | |
| SCHEMBL25968011 | 0.80 | ACHE (0.73) | SMN1; SMN2RECQLALDH1A1KDM4EPOLB | |
| SCHEMBL3285312 | 0.79 | DRD2 (0.65) | SMN1; SMN2RECQLALDH1A1ACHETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | WASE, NISHIKANT | 2020-03-05 | — | — | US | disclosed |
| US-20160312253-A1 | Compounds for Increasing Lipid Synthesis and Storage | INVITROGEN CORPORATION | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160312253-A1 | Compounds for Increasing Lipid Synthesis and Storage | FASN, LIPC, SREBF2 | SMN1; SMN2 4517/4885RECQL 2066/4885ALDH1A1 1121/4885 |
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | FASN, LIPC, SREBF2 | SMN1; SMN2 4517/4885RECQL 2066/4885ALDH1A1 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.